<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767987</url>
  </required_header>
  <id_info>
    <org_study_id>ISR IN-US-259-0139</org_study_id>
    <nct_id>NCT01767987</nct_id>
  </id_info>
  <brief_title>Ranolazine Cardioprotection in PCI</brief_title>
  <official_title>Ranolazine Cardioprotection in PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvey Hahn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kettering Health Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker
      release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ranolazine has been demonstrated to decrease angina, ischemia on perfusion imaging, improve
      diastolic function, and cardiac metabolism. Furthermore it has been associated with reduced
      cardiac arrhythmias, including non-sustained ventricular tachycardia and atrial fibrillation.
      It has not been studied as an acute cardioprotective agent in percutaneous coronary
      intervention (PCI).

      We hypothesize that upfront administration of Ranolazine could decrease the myocardial injury
      associated with PCI due to all the factors listed above (i.e. precondition the myocardium).
      We plan to screen all patients scheduled for an elective coronary angiogram. Those who meet
      criteria and consent will be randomized to either receive Ranolazine or placebo twice a day
      for 3 days leading up to the PCI.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated study due to lack of enrollment
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Troponin</measure>
    <time_frame>8-10 hrs post PCI</time_frame>
    <description>Troponin labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CK-MB</measure>
    <time_frame>8-10 hrs post PCI</time_frame>
    <description>CK-MB labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TIMI Flow Rate (Grade)</measure>
    <time_frame>TIMI Flow Rate (Grade) is assessed immediately after an interventional reperfusion attempt during a PCI (Percutaneous Coronary Intervention) procedure.</time_frame>
    <description>This TIMI classification was developed by the TIMI (Thrombolysis In Myocardial Infarction) study group to semiquantitatively assess coronary artery perfusion beyond point of occlusion on coronary angiography.* TIMI Grade [Description] TIMI 0 - no perfusion [no antegrade flow beyond the point of occlusion] TIMI 1 - penetration without perfusion [faint antegrade coronary flow beyond the occlusion with incomplete filling of the distal coronary bed] TIMI 2 - partial perfusion [delayed or sluggish antegrade flow with complete filling of the distal territory] TIMI 3 - complete perfusion [normal flow with complete filling of the distal territory]
*(see http://radclass.mudr.org/content/timi-grade-flow-grading-coronary-blood-flow-during-coronary-angiography) TIMI 0 is the least favorable grade. TIMI 3 is the most favorable grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Atrial Fibrillation, Ventricular Tachycardia, or Ventricular Fibrillation in Coronary Cath Lab</measure>
    <time_frame>During the PCI (Percutaneous Coronary Intervention) procedure - starting at timepoint of guidewire insertion into the access artery until removal of guidewire</time_frame>
    <description>Abnormal heart activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Non-sustained Ventricular Tachycardia or Atrial Fibrillation Post PCI</measure>
    <time_frame>Following completion of PCI through hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End Diastolic Pressure (LVEDP)</measure>
    <time_frame>During the PCI (Percutaneous Coronary Intervention) procedure - starting at timepoint of guidewire insertion into the access artery until removal of guidewire</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, Myocardial Infarction (Biomarker Greater Than 2x Normal), CHF, Cardiac Arrest</measure>
    <time_frame>At discharge or within 1 days, whichever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, MI, Revascularization, CHF</measure>
    <time_frame>1-4 weeks post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful PCI</measure>
    <time_frame>At discharge or within 1 days, whichever comes first</time_frame>
    <description>For the purposes of this study, a successful PCI is considered one where no additional coronary interventions were required within 24 hours after the initial PCI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment Intervention: Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Patients undergoing Coronary Angiography with possible PCI

          -  Able and willing to give consent

          -  Able to read and write English

        Exclusion Criteria:

          -  Current EKG or Biomarker of Acute Myocardial Infarction (MI) or Acute Coronary
             Syndromes (ACS)

          -  History of Allergy to Ranolazine

          -  Pregnant or Nursing

          -  Currently taking Ranolazine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harvey S Hahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kettering Health Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <results_first_submitted>September 9, 2014</results_first_submitted>
  <results_first_submitted_qc>October 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2015</results_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kettering Health Network</investigator_affiliation>
    <investigator_full_name>Harvey Hahn</investigator_full_name>
    <investigator_title>Director, Cardiovascular Fellowship Training Program and Director, Cardiac Noninvasive Laboratory</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>ACS</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>PCI</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>Coronary Angiogram</keyword>
  <keyword>Cardioprotectant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" lower_limit="51" upper_limit="66"/>
                    <measurement group_id="B2" value="67.5" lower_limit="65" upper_limit="70"/>
                    <measurement group_id="B3" value="63.5" lower_limit="51" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Troponin</title>
        <description>Troponin labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first</description>
        <time_frame>8-10 hrs post PCI</time_frame>
        <population>Of the 4 Ranolazine Group subjects, 1 was withdrawn for pre-procedure study drug non-compliance; 3 had no PCI intervention. Of the 2 Placebo Group subject, 1 had no PCI intervention. The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject undergoing this protocol required test.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Troponin</title>
          <description>Troponin labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first</description>
          <population>Of the 4 Ranolazine Group subjects, 1 was withdrawn for pre-procedure study drug non-compliance; 3 had no PCI intervention. Of the 2 Placebo Group subject, 1 had no PCI intervention. The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject undergoing this protocol required test.</population>
          <units>NG/ML</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CK-MB</title>
        <description>CK-MB labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first</description>
        <time_frame>8-10 hrs post PCI</time_frame>
        <population>For the single subject completing the PCI intervention, CK-MB was not done because the CK level was below the threshold running the CK-MB test.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>CK-MB</title>
          <description>CK-MB labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first</description>
          <population>For the single subject completing the PCI intervention, CK-MB was not done because the CK level was below the threshold running the CK-MB test.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TIMI Flow Rate (Grade)</title>
        <description>This TIMI classification was developed by the TIMI (Thrombolysis In Myocardial Infarction) study group to semiquantitatively assess coronary artery perfusion beyond point of occlusion on coronary angiography.* TIMI Grade [Description] TIMI 0 - no perfusion [no antegrade flow beyond the point of occlusion] TIMI 1 - penetration without perfusion [faint antegrade coronary flow beyond the occlusion with incomplete filling of the distal coronary bed] TIMI 2 - partial perfusion [delayed or sluggish antegrade flow with complete filling of the distal territory] TIMI 3 - complete perfusion [normal flow with complete filling of the distal territory]
*(see http://radclass.mudr.org/content/timi-grade-flow-grading-coronary-blood-flow-during-coronary-angiography) TIMI 0 is the least favorable grade. TIMI 3 is the most favorable grade.</description>
        <time_frame>TIMI Flow Rate (Grade) is assessed immediately after an interventional reperfusion attempt during a PCI (Percutaneous Coronary Intervention) procedure.</time_frame>
        <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom this protocol required data point was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>TIMI Flow Rate (Grade)</title>
          <description>This TIMI classification was developed by the TIMI (Thrombolysis In Myocardial Infarction) study group to semiquantitatively assess coronary artery perfusion beyond point of occlusion on coronary angiography.* TIMI Grade [Description] TIMI 0 - no perfusion [no antegrade flow beyond the point of occlusion] TIMI 1 - penetration without perfusion [faint antegrade coronary flow beyond the occlusion with incomplete filling of the distal coronary bed] TIMI 2 - partial perfusion [delayed or sluggish antegrade flow with complete filling of the distal territory] TIMI 3 - complete perfusion [normal flow with complete filling of the distal territory]
*(see http://radclass.mudr.org/content/timi-grade-flow-grading-coronary-blood-flow-during-coronary-angiography) TIMI 0 is the least favorable grade. TIMI 3 is the most favorable grade.</description>
          <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom this protocol required data point was collected.</population>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Atrial Fibrillation, Ventricular Tachycardia, or Ventricular Fibrillation in Coronary Cath Lab</title>
        <description>Abnormal heart activity</description>
        <time_frame>During the PCI (Percutaneous Coronary Intervention) procedure - starting at timepoint of guidewire insertion into the access artery until removal of guidewire</time_frame>
        <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom these protocol required data points were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Atrial Fibrillation, Ventricular Tachycardia, or Ventricular Fibrillation in Coronary Cath Lab</title>
          <description>Abnormal heart activity</description>
          <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom these protocol required data points were collected.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Non-sustained Ventricular Tachycardia or Atrial Fibrillation Post PCI</title>
        <time_frame>Following completion of PCI through hospital discharge</time_frame>
        <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom these protocol required data points were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Non-sustained Ventricular Tachycardia or Atrial Fibrillation Post PCI</title>
          <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom these protocol required data points were collected.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular End Diastolic Pressure (LVEDP)</title>
        <time_frame>During the PCI (Percutaneous Coronary Intervention) procedure - starting at timepoint of guidewire insertion into the access artery until removal of guidewire</time_frame>
        <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom this protocol required data point was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Diastolic Pressure (LVEDP)</title>
          <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom this protocol required data point was collected.</population>
          <units>mmHG</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death, Myocardial Infarction (Biomarker Greater Than 2x Normal), CHF, Cardiac Arrest</title>
        <time_frame>At discharge or within 1 days, whichever comes first</time_frame>
        <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom these protocol required data points were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Death, Myocardial Infarction (Biomarker Greater Than 2x Normal), CHF, Cardiac Arrest</title>
          <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom these protocol required data points were collected.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death, MI, Revascularization, CHF</title>
        <time_frame>1-4 weeks post PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Death, MI, Revascularization, CHF</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Successful PCI</title>
        <description>For the purposes of this study, a successful PCI is considered one where no additional coronary interventions were required within 24 hours after the initial PCI.</description>
        <time_frame>At discharge or within 1 days, whichever comes first</time_frame>
        <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom these protocol required data points were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Successful PCI</title>
          <description>For the purposes of this study, a successful PCI is considered one where no additional coronary interventions were required within 24 hours after the initial PCI.</description>
          <population>The only subject undergoing PCI intervention was from the Placebo Group and was thus the only subject for whom these protocol required data points were collected.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from time of consent through end of study discharge from hospital. Adverse events unresolved at discharge were to be followed to resolution. No events occuring after discharge were to be recorded as adverse events.</time_frame>
      <desc>Study timeline consisted of consent, pre-procedure medication (3 days), arrival for out-patient heart cath procedure, possible PCI, post-procedure recovery time, and discharge from hospital recovery room. Time from consent to start of study meds varied. Time from start of study drug to discharge was 4 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>Oral treatment Intervention: Drug: Ranolazine 1000 mg
Ranolazine: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral treatment Intervention: Drug: Placebo
Placebo: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suzanne Coleman, PhD</name_or_title>
      <organization>Kettering Health Network</organization>
      <phone>937-395-8390</phone>
      <email>suzanne.coleman@khnetwork.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

